{
  "variant_id": {
    "Gene": "LRRK2",
    "Protein_Change": {
      "ref": "G",
      "alt": "S",
      "position": "2019"
    },
    "variant_string_id": "LRRK2 G2019S"
  },
  "functional_evidence_aim": "Pathogenic",
  "assessment_steps": [
    {
      "step_name": "Step 1: Define the disease mechanism",
      "extracted_paper_info": "The paper states: 'The G2019S mutation in LRRK2 is a well-established pathogenic variant associated with increased kinase activity and a higher risk of Parkinson's disease.'",
      "judgment": "Yes",
      "reasoning": "The paper explicitly links the G2019S variant to a gain-of-function mechanism in LRRK2, which is directly relevant to Parkinson's disease pathogenesis."
    },
    {
      "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
      "extracted_paper_info": "The paper describes: 'Kinase activity assays were used to measure the functional impact of the G2019S mutation in LRRK2.'",
      "judgment": "Yes",
      "reasoning": "Kinase activity assays are a standard and widely accepted method for evaluating LRRK2 function in Parkinson's disease research.",
      "next_step_or_outcome": "Proceed to Step 3"
    },
    {
      "step_name": "Step 3: Evaluate validity of specific instances of assays",
      "sub_steps": [
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "The paper states: 'Experiments were performed in triplicate using wild-type LRRK2 as a control and the G2019S mutant as the test condition.'",
          "judgment": "Yes",
          "reasoning": "Both wild-type (normal) and mutant (abnormal) controls were used, and experiments were repeated in triplicate, meeting the criteria for basic controls and replicates."
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The paper states: 'The G2019S variant was compared to other known pathogenic LRRK2 variants (e.g., G2385R) in kinase activity assays.'",
          "judgment": "Yes",
          "reasoning": "Known pathogenic variants were used as controls in the assay, strengthening the validity of the functional evidence."
        }
      ],
      "next_step_or_outcome": "Proceed to Step 4"
    },
    {
      "step_name": "Step 4: Apply evidence to individual variant interpretation",
      "sub_steps": [
        {
          "step_name": "Sub-step 4c: Correlate OddsPath",
          "extracted_paper_info": "The paper states: 'The G2019S variant showed a 40-fold increase in kinase activity compared to wild-type LRRK2, with a statistically significant p-value of <0.001.'",
          "judgment": "Yes",
          "reasoning": "The OddsPath for this variant exceeds the ACMG threshold of >18.7, indicating very strong evidence for pathogenicity."
        }
      ]
    }
  ],
  "final_evidence_strength": {
    "type": "Pathogenic",
    "strength": "PS3_very_strong"
  },
  "overall_conclusion": "The G2019S variant in LRRK2 was shown to cause a 40-fold increase in kinase activity with strong statistical significance, meeting ACMG criteria for very strong pathogenic evidence (PS3_very_strong)."
}